Glaxo Preparing With J&J to Test A New Series of AIDS Drugs
GSK and J&J have released a new AIDS drug to transform the outlook of the disease. New pharmaceutical candidates will be needed for proper promotion of these products to various markets.
The study will build on the drugs’ success as a combination of daily pills when pitted against Bristol-Myers Squibb Co. (BMY)’s Sustiva. A trial showed that Glaxo’s GSK1265744 and J&J’s Edurant helped a higher percentage of patients than Sustiva when given with other drugs commonly used to control the virus, according to data presented today at a conference.
Once treated with as many as 30 tablets a day, HIV is now subdued with a once-daily pill such as Gilead Sciences Inc. (GILD)’s Atripla. Glaxo released data yesterday that showed its medicine may also prevent HIV infection when given once every three months. Long-acting AIDS drugs would alleviate the inconvenience and side effects of daily pill-taking, said Kenneth Mayer, medical research director of the Fenway Institute in Boston.
“These drugs are leading the way” toward longer-acting treatments, John Pottage, chief scientific and medical officer for ViiV Healthcare, the venture of London-based Glaxo, New York-based Pfizer Inc. and Osaka, Japan-based Shionogi & Co. that is developing GSK1265744.
The drug is a version of Glaxo’s Tivicay, which won U.S. regulatory approval in August. New Brunswick, New Jersey-based J&J’s Edurant was approved in 2011. A trial of monthly injections of the two drugs will start in the next few months, with results expected in 2016, Pottage said.
Representatives will be needed for these new products once they are ready to hit the market. It is important for entry level candidates for pharmaceutical sales positions to meet the employer requirements to successfully obtain interviews. Industry recruiters and human resource professionals look for applicants with pharmacology and science education. The CNPR® Certification training and certification provides such education which will lead to meeting minimum pharmaceutical sales requirements.
One reason that pharmaceutical companies prefer industry education and training is because they look to get newly hired candidates quickly out into a sales territory. If the new employee has limited training in pharmacology or the medical field then their training could last many weeks or months. This typically means no physician coverage for the assigned territory of the new employee while they are being trained. Thus the territories market share could be affected the longer it takes to train a new sales rep.
When pharmaceutical companies look at applicants who have no experience as a pharmaceutical sales rep they look for a combination of sales ability/experience and medical/pharmacology education. It is important to include both types of skills on your resume. The CNPR® program was designed to provide aspiring pharmaceutical sales vocational skills that pharmaceutical employers seek. The program provides training in clinical pharmacology, pharmaceutical selling rules, regulations, drug distribution channels, therapeutic drug classes, pharmacokinetics, etc. A pharmaceutical sales rep cannot successfully sell to physicians without having strong pharmacology/
Pharmaceutical companies will require their new hires to understand pharmacology, medical terminology, selling guidelines, understanding relevant disease areas and much more before they send them out into the field. The CNPR® Certification program will cover "need to know" information about diseases and products that treat them. The tests that a new hire must be able to pass covers: disease background; anatomy and physiology to the disease; signs, symptoms, and diagnostic procedures; current treatment alternatives;
For more information on training for pharmaceutical sales, contact the NAPSRx (National Association of Pharmaceutical Sales Representatives)
Sources: Bloomberg News, NAPSRx